Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer

British Journal of Cancer

Volumn 83, Issue 11, 2000, Pages 1480-1487

  Pierga, J Y ^a   Mouret, E ^a   Dieras V ^a   Laurence, V ^a   Beuzeboc, P ^a   Dorval, T ^a   Palangie T ^a   Jouve, M ^a   Vincent Salomon, A ^a   Scholl, S ^a   Extra, J M ^a   Asselain, B ^a   Pouillart, P ^a  

^a INSTITUT CURIE   (France)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Pathological nodal metastasis

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; THIOTEPA;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0033671631     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1461     Document Type: Article

References (41)

1. Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer
2. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute
3. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast
4. Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy
5. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
6. Prediction of response to primary chemotherapy for operable breast cancer
7. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer
8. Regression models and life tables
9. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer
10. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update
11. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
12. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
13. Prognostic significance of axillary involvement after preoperative chemotherapy in stage III breast cancer
14. Locally advanced non-metastatic breast cancer: Analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach
15. Treatment of curable carcinoma of the breast
16. Primary chemotherapy in breast cancer: Significantly enhanced clinical and pathological response with docetaxel
17. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma
18. Nonparametric estimation from incomplete observations
19. The sentinel node in breast cancer - A multicenter validation study
20. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer
21. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
22. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy
23. Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi
24. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma
25. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas
26. Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies
27. Evaluation of survival data and two new rank order statistics arising in its consideration
28. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Seth (IBBGS)
29. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer
30. Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons
31. Toxicity and response criteria of the Eastern Cooperative Oncology Group
32. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer
33. Discouraging news for high-dose chemotherapy in high-risk breast cancer
34. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy
35. Prognostic value of the S-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy
36. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome
37. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6
38. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival
39. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer
40. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer
41. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients